The Vessix Vascular V2 Renal Denervation System™ has received CE Mark in Europe and TGA approval in Australia. The V2 Renal Denervation System is an investigational device and not available for use or sale in the United States.

The Vessix Vascular V2 Renal Denervation System™ has received CE Mark in Europe and TGA approval in Australia. The V2 Renal Denervation System is an investigational device and not available for use or sale in the United States.

The Vessix Vascular V2 Renal Denervation System™ has received CE Mark in Europe and TGA approval in Australia. The V2 Renal Denervation System is an investigational device and not available for use or sale in the United States.

• Download Hi-Res (9.5 MB)

The TruePath CTO Device has received 510(k) clearance from the U.S. Food and Drug Administration and carries CE mark approval.

The TruePath CTO Device has received 510(k) clearance from the U.S. Food and Drug Administration and carries CE mark approval.

• Download Hi-Res (2.2 MB)

Boston Scientific Corporation announced CE Mark and European market launch of the Innova™ Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA) in May of 2012. In the U.S., the Innova Stent System is an investigational device, limited by applicable law to investigational use only and not available for sale.

• Download Hi-Res (270 KB)

In May of 2012, Boston Scientific Corporation announced U.S. Food and Drug Administration approval and market launch of the Epic™ Vascular Self-Expanding Stent System. It received CE Mark approval and was launched in Europe and other international markets in 2009.

• Download Hi-Res (19.3 MB)